Updated:
TCG Crossover Management
TCG Crossover (TCGX) is a science-driven investment firm dedicated to advancing disruptive medicines. It is an investment firm focused on innovative biotech...
TCG Crossover Management
TCG Crossover (TCGX) is a science-driven investment firm dedicated to advancing disruptive medicines. It is an investment firm focused on innovative biotech companies, investing in visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines. With offices in Palo Alto, San Francisco, and New York City, it has supported companies in North America, Europe, and China. The firm invests out of closed-end funds and supports private and public companies building the future of medicine.
General information
Firm type
Private Equity
Year founded
2020
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Principals
Chen Yu
Managing Partner and founder
Cariad Chester
Managing Partner
Giuliano Marostica
Managing Partner
Dandan Dong
Venture Partner
George Feng
Associate (Bioengineer)
Bill Zhang
Analyst
Haithem Laaribi
Associate
Suan Tuang
Associate
Michael Albert
Associate
Craig Skaling
COO & CFO
Brad Balter
Head of Trading
Ed Amorosi
Head of Capital Formation & Investor Relations
Jing Wu
Controller
Echo Qin
Senior Accounting Manager
Kate Garcia
Operations
Robert Tjian
PhD, Science Partner
Roger Perlmutter
MD, Science Partner
Charles Sawyers
MD, Science Partner
Richard Scheller
PhD, Science Partner
Vishva M. Dixit
MD, Science Partner
Huda Y. Zoghbi
MD, Science Partner
Charles Zuker
PhD, Science Partner
Helen Hobbs
PhD, Science Partner
Sector focus
Frequently asked questions
How does TCG Crossover's crossover mandate actually work in practice?
The firm invests across a company's transition from late-stage private funding rounds through IPO and into the public aftermarket. This means writing equity checks in pre-IPO crossover rounds, participating in the IPO allocation, and managing post-IPO positions rather than distributing or selling at the lockup expiry. The mandate concentrates on 10 to 14 core positions.
Does TCG Crossover participate in fund commitments or only direct deals?
The firm focuses on direct equity investments — both private placement rounds in late-stage companies and public-market equity positions in newly listed issuers. There is no public record of TCG Crossover allocating capital to third-party venture funds as a limited partner.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: